Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Primary:
• To compare the efficacy of nasal fentanyl (NF) to oral transmucosal fentanyl (Actiq®)
(hereafter Actiq) in the management of breakthrough pain in cancer patients.
Secondary:
- To compare patients' general impression and preference of NF and Actiq
- To explore the relationship between NF doses and dose of current opioid for breakthrough
pain (BTP) and the relationship between dose of NF and of background opioid
- To assess safety and tolerability of NF